-
公开(公告)号:US11845715B2
公开(公告)日:2023-12-19
申请号:US17405989
申请日:2021-08-18
申请人: THE UNIVERSITY OF QUEENSLAND , THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
发明人: Luke O'Neill , Rebecca Coll , Matthew Cooper , Avril Robertson , Kate Schroder
IPC分类号: C07C311/56 , A61P17/00 , C07D403/12 , C07D249/12 , C07D249/04 , C07D241/42 , A61P25/00 , A61P37/00 , C07D495/04 , C07D241/44 , C07D277/36 , C07D307/68 , C07D487/04 , C07D215/36 , C07D249/06 , C07D311/16 , C07D401/06 , C07D401/12 , A61P3/00 , C07C311/60 , C07D213/71 , C07D217/22 , C07D221/18 , C07D317/62 , C07D333/34 , A61P1/00 , A61P35/00 , C07D217/02 , C07D241/24 , C07D271/12 , C07D413/12 , C07D417/12 , A61P5/00 , C07D307/18 , C07D307/64 , C07D311/60 , C07D333/52 , C07D333/62 , C07D405/12 , C07D495/06 , C07D217/24 , C07D235/02 , C07D311/18 , C07D407/12 , C07D231/18 , C07D307/82 , C07D309/08 , C07D493/04 , C07D207/38 , C07D261/18 , C07D498/04
CPC分类号: C07C311/56 , A61P1/00 , A61P3/00 , A61P5/00 , A61P17/00 , A61P25/00 , A61P35/00 , A61P37/00 , C07C311/60 , C07D207/38 , C07D213/71 , C07D215/36 , C07D217/02 , C07D217/22 , C07D217/24 , C07D221/18 , C07D231/18 , C07D235/02 , C07D241/24 , C07D241/42 , C07D241/44 , C07D249/04 , C07D249/06 , C07D249/12 , C07D261/18 , C07D271/12 , C07D277/36 , C07D307/18 , C07D307/64 , C07D307/68 , C07D307/82 , C07D309/08 , C07D311/16 , C07D311/18 , C07D311/60 , C07D317/62 , C07D333/34 , C07D333/52 , C07D333/62 , C07D401/06 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/12 , C07D413/12 , C07D417/12 , C07D487/04 , C07D493/04 , C07D495/04 , C07D495/06 , C07D498/04 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2602/08 , C07C2602/10 , C07C2603/10
摘要: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.
-
公开(公告)号:US20230339960A1
公开(公告)日:2023-10-26
申请号:US18342977
申请日:2023-06-28
申请人: Pfizer Inc.
发明人: JOHN DAVID TRZUPEK , KATHERINE LIN LEE , MARK EDWARD BUNNAGE , SEUNGIL HAN , DAVID HEPWORTH , FRANK ELDRIDGE LOVERING , JOHN PAUL MATHIAS , NIKOLAOS PAPAIOANNOU , BETSY SUSAN PIERCE , JOSEPH WALTER STROHBACH , STEPHEN WAYNE WRIGHT , CHRISTOPH WOLFGANG ZAPF , LORI KRIM GAVRIN , ARTHUR LEE , DAVID RANDOLPH ANDERSON , KEVIN JOSEPH CURRAN , CHRISTOPH MARTIN DEHNHARDT , EDDINE SAIAH , JOEL ADAM GOLDBERG , XIAOLUN WANG , HORNG-CHIH HUANG , RICHARD VARGAS , MICHAEL DENNIS LOWE , AKSHAY PATNY
IPC分类号: C07D491/056 , C07F7/18 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C69/94 , C07D207/08 , C07D207/26 , C07D207/267 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D498/04 , A61K31/40
CPC分类号: C07D491/056 , C07F7/1804 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C69/94 , C07D207/08 , C07D207/26 , C07D207/267 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D498/04 , A61K31/40
摘要: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia,
as defined in the specification. In an embodiment, a pharmaceutical composition can be in a liquid dosage form and can comprise a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent. In another embodiment, a method of adjuvant treating a disorder or condition can comprising administering the pharmaceutical composition to a patient.-
公开(公告)号:US20230331711A1
公开(公告)日:2023-10-19
申请号:US18337565
申请日:2023-06-20
发明人: John BURNIER , Thomas GADEK , Frederic NAUD
IPC分类号: C07D405/06 , C07D217/26 , A61K31/4709 , A61P27/04 , A61K31/4725 , A61K45/06 , C07D405/10 , A61K9/06 , A61K9/08 , A61K47/02 , A61K47/06 , A61K47/10 , A61K47/14 , A61K47/22 , A61K47/38 , C07C317/48 , C07D217/02 , C07D217/04
CPC分类号: C07D405/06 , C07D217/26 , A61K31/4709 , A61P27/04 , A61K31/4725 , A61K45/06 , C07D405/10 , A61K9/06 , A61K9/08 , A61K47/02 , A61K47/06 , A61K47/10 , A61K47/14 , A61K47/22 , A61K47/38 , C07C317/48 , C07D217/02 , C07D217/04 , A61K47/183
摘要: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
-
公开(公告)号:US11643388B2
公开(公告)日:2023-05-09
申请号:US17246014
申请日:2021-04-30
发明人: Dean Sheppard , William F. DeGrado , Aparna Sundaram , Hyunil Jo , Richard Beresis , Marc Adler
IPC分类号: C07C275/26 , C07C275/24 , A61P11/06 , C07D205/04 , C07D213/73 , C07D217/02 , C07D217/06 , C07D239/84
CPC分类号: C07C275/26 , A61P11/06 , C07C275/24 , C07D205/04 , C07D213/73 , C07D217/02 , C07D217/06 , C07D239/84
摘要: Disclosed herein, inter alia, are inhibitors of alpha 2 beta 1 integrin and methods of using the same.
-
5.
公开(公告)号:US20230089267A1
公开(公告)日:2023-03-23
申请号:US17886926
申请日:2022-08-12
IPC分类号: A61K31/198 , C07C235/34 , C07D319/18 , C07D217/02 , C07D213/65 , C07D235/06 , A61K31/357 , A61K31/472 , A61K31/44 , A61K31/4184 , A61P25/28 , A61P37/06 , A61K9/00 , A61K9/08 , A61K47/40
摘要: Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intolerance in a subject, for example, to treat autoimmune disorders, or in combination with an antigenic therapy, such as a protein or gene therapy, to improve the efficacy of the antigenic therapy. The compounds have the following structural formula: wherein values for the variables (e.g., Ring A, L, R1, R2, R3, m) are as described herein.
-
公开(公告)号:US20220411366A1
公开(公告)日:2022-12-29
申请号:US17246014
申请日:2021-04-30
发明人: Dean Sheppard , William F. DeGrado , Aparna Sundaram , Hyunil Jo , Richard Beresis , Marc Adler
IPC分类号: C07C275/26 , A61P11/06 , C07D239/84 , C07D205/04 , C07D213/73 , C07D217/02 , C07D217/06 , C07C275/24
摘要: Disclosed herein, inter alia, are inhibitors of alpha 2 beta 1 integrin and methods of using the same.
-
公开(公告)号:US11535595B2
公开(公告)日:2022-12-27
申请号:US17296469
申请日:2019-12-16
发明人: Kengo Sumi , Ryohei Nakamura
IPC分类号: C07D217/22 , C07D217/02
摘要: A compound, such as isoquinoline-6-sulfonyl chloride acid and/or addition salts thereof, may be useful as a manufacturing intermediate for an isoquinoline-6-sulfonamide compound. A method for manufacturing such compounds and/or or acid addition salts thereof, may involve subjecting 6-(benzylthio)isoquinoline to an oxidative chlorination reaction and/or reacting 6-aminoisoquinoline with a nitrite or nitrous acid ester, then with thionyl chloride, and then with an acid.
-
公开(公告)号:US11478461B2
公开(公告)日:2022-10-25
申请号:US17047247
申请日:2019-04-15
发明人: Liangqin Guo , Hongjun Zhang , Ping Chen , Dane Clausen , Xavier Fradera , Yongxin Han , Shuwen He , Xianhai Huang , Alexander Pasternak , Qinglin Pu , Li Xiao , Feng Ye
IPC分类号: A61K31/44 , A61K45/06 , C07C237/22 , C07C255/60 , C07D213/75 , C07C271/36 , C07C233/78 , C07C271/24 , C07C233/79 , C07D213/81 , C07D271/06 , C07D239/28 , C07D215/48 , C07C275/30 , C07C275/28 , C07D239/42 , C07D305/06 , C07D261/08 , C07D471/04 , C07D261/20 , C07D209/34 , C07D277/56 , C07D217/02 , C07D231/14 , C07D237/28 , C07D241/24 , C07D217/26 , A61K31/167 , A61K31/27 , A61K31/4245 , A61K31/47 , A61K31/17 , A61K31/505 , A61K31/337 , A61K31/437 , A61K31/42 , A61K31/426 , A61K31/472 , A61K31/415 , A61K31/4965
摘要: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
-
公开(公告)号:US20220332726A1
公开(公告)日:2022-10-20
申请号:US17298676
申请日:2020-11-18
发明人: Wang SHEN , Kui Feng DANG , Chao ZHANG , Chunming CHEN , Li Hong SHAN , Wen DING , Xin WANG , Jia Chen MI , Ya Bo SUN , Xia Xin SHENG , Jia Lei SHEN , YONG LI
IPC分类号: C07D495/04 , C07D217/02 , C07D217/26 , C07D275/04
摘要: A small molecule compound of a NO donor is a compound shown in the following structural formula I or a stereoisomer, a geometric isomer, a tautomer, a racemate, a deuterated isotopic derivative, a hydrate, a solvate, a metabolite, or a pharmaceutically acceptable salt or prodrug thereof; wherein a ring A is a substituted or unsubstituted heteroaromatic ring; X is selected from (CH2); R is a substituent of terminal —O—NO2; R1 is selected from hydrogen, a hydroxyl group, a halogen, an amino group, a cyano group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, or a substituted or unsubstituted heteroalkyl group; R2 and R3 are each independently selected from hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, or an amino protecting group.
-
公开(公告)号:US20220112159A1
公开(公告)日:2022-04-14
申请号:US17405989
申请日:2021-08-18
申请人: THE UNIVERSITY OF QUEENSLAND , THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOL
发明人: Luke O'NEILL , Rebecca Coll , Matthew Cooper , Avril Robertson , Kate Schroder
IPC分类号: C07C311/56 , A61P17/00 , C07D403/12 , C07D249/12 , C07D249/04 , C07D241/42 , A61P25/00 , A61P37/00 , C07D495/04 , C07D241/44 , C07D277/36 , C07D307/68 , C07D487/04 , C07D215/36 , C07D249/06 , C07D311/16 , C07D401/06 , C07D401/12 , A61P3/00 , C07C311/60 , C07D207/38 , C07D213/71 , C07D217/22 , C07D221/18 , C07D317/62 , C07D333/34 , A61P1/00 , A61P35/00 , C07D217/02 , C07D241/24 , C07D271/12 , C07D413/12 , C07D417/12 , A61P5/00 , C07D261/18 , C07D307/18 , C07D307/64 , C07D311/60 , C07D333/52 , C07D333/62 , C07D405/12 , C07D495/06 , C07D217/24 , C07D235/02 , C07D311/18 , C07D407/12 , C07D231/18 , C07D307/82 , C07D309/08 , C07D493/04 , C07D498/04
摘要: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.
-
-
-
-
-
-
-
-
-